COMP <GO>
RMD vs MDLN // EV/EBITDA & P/E VALUATION
ResMed Inc. (NYSE) VS. Medline Inc. (NASDAQ) • 15-METRIC TALLY: RMD 8
— MDLN 4
▲ EV/EBITDA & P/E VALUATION LEADER: RMD
LAST: $229.94 (-9.05%) • MKT CAP: $35.56B
valuation
19.9x
LAST: $32.12 (+0.38%) • MKT CAP: $42.07B
valuation
20.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RMD VS. MDLN)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | RMD | MDLN | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 59.40% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 22.90% | 8.20% | +14.70 | RMD | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 19.9x | 20.3x | -0.40 | RMD | /valuation <GO> |
| Free Cash Flow Yield | 4.67% | 3.08% | +1.59 | RMD | /fcf-yield <GO> |
| Operating Margin | 32.70% | 7.80% | +24.90 | RMD | /operating-margins <GO> |
| Net Profit Margin | 27.20% | 68.00% | -40.80 | MDLN | /net-margins <GO> |
| Revenue Growth (YoY) | 9.80% | 11.50% | -1.70 | MDLN | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.87% | 0.00% | +0.87 | RMD | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 12.49 | 2.50 | +9.99 | RMD | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 5/9 | +4.00 | RMD | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 60.1 | 30.9 | +29.20 | RMD | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.93 | 1.11 | -0.18 | MDLN | /macro-sensitivity <GO> |
| Forward P/E Multiple | 23.6x | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $35.56B | $42.07B | -$6.51B | MDLN | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | RMD REV | MDLN REV | RMD GROSS % | MDLN GROSS % | RMD FCF | MDLN FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $5.15B | $28.43B | 59.4% | 26.4% | $1.66B | $1.30B |
| FY 2024 | $4.69B | $25.51B | 56.7% | 27.3% | $1.30B | $1.42B |
| FY 2023 | $4.22B | $23.23B | — | — | $503.3M | $639.6M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RMD // BETA 0.93
MDLN // BETA 1.11